Breaking News Instant updates and real-time market news.

HIMX

Himax

$8.09

0.08 (1.00%)

, GME

GameStop

$21.02

-0.14 (-0.66%)

07:30
07/17/17
07/17
07:30
07/17/17
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Friday in Himax (HIMX), GameStop (GME), Calpine (CPN), and Axovant Sciences (AXON).

HIMX

Himax

$8.09

0.08 (1.00%)

GME

GameStop

$21.02

-0.14 (-0.66%)

CPN

Calpine

$13.87

0.12 (0.87%)

AXON

Axovant Sciences

$24.28

0.36 (1.51%)

  • 17

    Jul

  • 18

    Jul

  • 03

    Aug

  • 05

    Sep

HIMX Himax
$8.09

0.08 (1.00%)

05/11/17
LSCM
05/11/17
DOWNGRADE
LSCM
Hold
Himax downgraded to Hold from Buy at Lake Street
04/17/17
MACQ
04/17/17
INITIATION
Target $40
MACQ
Outperform
Himax initiated with an Outperform at Macquarie
Macquarie analyst Lynn Luo initiated Himax with an Outperform and a $40 price target saying the company is well positioned to ride on the 3D sensing trend with capability in both components and total solutions. Luo forecasts Himax's revenue will grow 7%/26% in 2017/18, and with margin expansion in 3D sensing, she estimates Himax's earnings will grow 32%/55% in 2017/18.
04/17/17
04/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ProPetro Holding (PUMP) initiated with a Buy at Tudor Pickering. 2. Canadian Solar (CSIQ) initiated with a Buy at Axiom. 3. Bright Horizons (BFAM) assumed with an Outperform at Credit Suisse. 4. Sientra (SIEN) initiated with a Buy at Lake Street. 5. Himax (HIMX) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/17
MACQ
04/17/17
INITIATION
Target $40
MACQ
Outperform
Himax initiated with an Outperform at Macquarie
Macquarie analyst Lynn Luo initiated Himax with an Outperform and a $40 price target saying the company is well positioned to ride on the 3D sensing trend with capability in both components and total solutions. Luo forecasts Himax's revenue will grow 7%/26% in 2017/18, and with margin expansion in 3D sensing, she estimates Himax's earnings will grow 32%/55% in 2017/18.
GME GameStop
$21.02

-0.14 (-0.66%)

03/27/17
03/27/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Michaels (MIK) downgraded to Neutral from Overweight at Piper Jaffray with analyst Peter Keith citing his firm's Spring women's survey which showed 30%-40% of arts and crafts purchases are completed online. Further, the analyst's pricing analysis versus Amazon (AMZN) suggests Michaels is at a "notable premium" on 50 like-for-like items. Keith sees potential for price investment by Michaels over the coming years to make itself more competitive with Amazon. 2. Intuit (INTU) downgraded to Buy from Conviction Buy at Goldman with analyst Jesse Hulsing citing the more challenging Consumer Tax environment. Software/do-it-yourself share gains versus assisted are down versus prior years, including Intuit's, the analyst wrote. As a result, Hulsing lowered Inuit estimates and trimmed its price target to $134 from $135. 3. GameStop (GME) downgraded to Neutral from Buy at Hilliard Lyons with analyst Jeffrey Thomison saying 2017 guidance was "underwhelming" and he has increased concerns regarding the core video game retailing business. 4. Morgan Stanley (MS) downgraded to Sell from Neutral at Compass Point with analyst Charles Peabody saying he views shares as overvalued based on the elongated trajectory towards earning a competitive ROE and most of the benefits of Project Streamline have been priced in or realized. 5. KB Home (KBH) downgraded on valuation at JMP Securities with analyst Peter Martin downgraded the stock based on valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/01/17
RHCO
05/01/17
NO CHANGE
RHCO
GameStop to benefit from higher Switch production, says SunTrust
After Nintendo increased its production of the Switch console by 25%, SunTrust analyst David Magee says that the increase is positive for GameStop (GME). He thinks that the Switch will boost the retailer's comp sales growth by 1%-4% in 2017 and could raise its profit by 10%. According to the analyst, little of these increases are incorporated into Street estimates. He keeps a $28 price target and a Buy rating on the shares.
05/26/17
LOOP
05/26/17
NO CHANGE
Target $28
LOOP
Buy
GameStop shortfall in Technology Brands a reason for pause, says Loop Capital
Loop Capital analyst Anthony Chukumba believes GameStop's Technology Brands business heavily influences investor perception of the company's "terminal value" and he sees the profitability shortfall in that segment as something that gives him pause at a time when he says the company doesn't need "another thing to worry about." Noting GameStop reported much better than expected Q1 results in spite of the Tech Brands profit issue, Chukumba keeps a Buy rating on the stock, citing valuation.
05/26/17
MZHO
05/26/17
NO CHANGE
MZHO
GameStop should be bought on weakness, says Mizuho
Mizuho analyst San Phan says that the decline in GameStop's stock was caused by its unchanged fiscal 2017 guidance and the 2% year-over-year decline in the operating income of its tech brands business. The analyst says that the company's guidance is conservative, and he is more upbeat on the company;s outlook due to the success of the Nintendo (NTDOY) Switch. He strongly recommends buying GameStop's shares on weakness.
CPN Calpine
$13.87

0.12 (0.87%)

05/11/17
SBSH
05/11/17
NO CHANGE
Target $15
SBSH
Buy
Calpine takeout could happen at $14-$15 per share, says Citi
After the Wall Street Journal yesterday reported Calpine is exploring a sale, Citi analyst Praful Mehta says he believes the company could be worth $14-$15 per in share in a buyout. The stock closed yesterday up 18% to $11.89. The analyst thinks a sale could generate "good interest" from private equity. He keeps a Buy rating on Calpine with a $15 price target.
05/11/17
DBAB
05/11/17
NO CHANGE
Target $14
DBAB
Buy
Calpine unlikely to go private above $16 per share, says Deutsche Bank
Deutsche Bank analyst Abe Azar sees few strategic acquirers for Calpine (CPN), making going private or remaining public the most likely outcomes in his view. The Wall Street Journal reported yesterday that the company is exploring a sale. Market power issues in Texas make a combination with Vistra Energy (VST) or NRG Energy (NRG) unlikely, and while PSEG (PEG) and Exelon (EXC) could afford buying Calpine, such a deal would be a shift in strategy for both. The analyst finds it unlikely that a go-private deal gets done much north of $16 per share. He believes, however, that a mid-teens per share takeout is possible "with some creative structuring." Even without a deal, Calpine offers value based on its cash flow profile, Azar contends. The analyst reiterates a Buy rating on Calpine with a $14 price target.
05/24/17
FBCO
05/24/17
NO CHANGE
FBCO
Outperform
Exelon a net winner despite 'disappointing' 2020/21 auction, says Credit Suisse
Following PJM Interconnection's annual capacity auction, Credit Suisse analyst Michael Weinstein called Exelon a net winner despite "disappointing" RPM results for the 2020/21 capacity auction. The results for the EMAAC area should help drive a net positive result for Exelon assuming the same amount of capacity cleared year-over-year, he indicated. PSEG (PEG) and Calpine (CPN)are also "net beneficiaries," while Dynegy (DYN), NRG Energy (NRG) and FirstEnergy (FE) will "bear the brunt of a poor RTO showing," Weinstein tells investors.
06/20/17
SBSH
06/20/17
NO CHANGE
SBSH
Citi sees increasing likelihood of Vistra acquiring Dynegy
After hosting investor meetings with managements in Texas, Citi analyst Praful Mehta believes the likelihood of a Dynegy (DYN) acquisition by Vistra Energy (VST) is increasing. He views price as the "likely gating item" and continues to expect an $11-$12 per share buyout price for Dynegy in an all stock deal. Vistra management seems "more open to the deal than we originally interpreted," Mehta tells investors in a research note. The analyst also believes a private equity exit for Calpine (CPN) is increasing likely as the company continues with its reported sale process.
AXON Axovant Sciences
$24.28

0.36 (1.51%)

06/14/17
OPCO
06/14/17
NO CHANGE
Target $30
OPCO
Outperform
Axovant Sciences price target raised to $30 from $26 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Axovant Sciences to $30 after leaving a meeting with management "incrementally more positive." The analyst is "encouraged" by management's vision which he says extends beyond dementia into other areas of high unmet need within neurology. He believes the focus on dementia with Lewy bodies and Lewy body dementia, which includes Parkinson's disease dementia, could "create significant value for shareholders." Olson sees a favorable risk/reward profile for intepirdine in the Phase 3 Mindset study with top-line results due in late September. He keeps an Outperform rating on Axovant.
04/17/17
JEFF
04/17/17
NO CHANGE
Target $31
JEFF
Buy
Jefferies sees Axovant shares hitting $5 or $90 on Sept. data
Jefferies analyst Biren Amin last week hosted investor meetings with Axovant Sciences' incoming CEO David Hung and Vivek Ramaswamy, who is transitioning to CEO of privately held Roivant. He notes the stock is up 45% since the announcement. "This is the stupidest thing I've ever heard," Hung said of the investor theory that he believes intepirdine will fail, Amin tells investors in a research note. It seems Axovant's profile fit what Hung was looking for and he conducted extensive due diligence on both intepirdine and nelotanserin, the analyst writes. He adds that the new CEO believes both products, in aggregate, offer five opportunities for value creation. Regarding the late September Phase III readout for intepirdine in mild to moderate Alzheimer's disease, Amin believes Axovant shares could trade to $80-$90 with strong improvement on the Alzheimer's disease assessment scale, or ADS-cog, of 1.5 point at 24 weeks and positive ADCS-adl, or Alzheimer's disease cooperative study - activities of daily living outcome. With a more moderate outcome where ADS-cog ranges between 0.7 and 1.3 point improvement and ADCS-adl does not achieve statistical significance, the analyst thinks the shares could still range higher to $45-$50. If the Mindset trial fails, he thinks the shares could drop to $5. Axovant closed Thursday up $2.20 to $22.
04/12/17
OPCO
04/12/17
NO CHANGE
Target $26
OPCO
Outperform
Axovant Sciences price target raised to $26 from $20 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Axovant Sciences to $26 from $20 based on a larger market opportunity for nelotanserin focused on motor symptoms. The analyst notes that shares have rallied since the company announced that it has appointed David Hung as CEO. He reiterates an Outperform rating on the shares.
04/11/17
BARD
04/11/17
NO CHANGE
Target $29
BARD
Outperform
Baird incrementally positive on Axovant Sciences following CEO hire
Baird analyst Brian Skorney said he was impressed by Axovant Sciences' announcement of hiring Dr. David Hung as its CEO, noting that Hung headed Medivation and was the architect behind last year's biggest biotech takeout. He sees the hiring of Hung as sign of confidence in Axovant's MINDSET Alzheimer drug trial. Skorney reiterated his Outperform rating and $29 price target on Axovant Sciences shares. The Fly notes Axovant priced a secondary offering of 6.74M shares at $18.54 earlier today after the stock advanced 22.5% to close at $18.54 yesterday.

TODAY'S FREE FLY STORIES

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:29
07/20/17
07/20
10:29
07/20/17
10:29
Hot Stocks
Breaking Hot Stocks news story on Steel Dynamics »

Steel Dynamics says very…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

XOM

Exxon Mobil

$81.30

0.45 (0.56%)

10:29
07/20/17
07/20
10:29
07/20/17
10:29
Periodicals
Exxon Mobil fined $2M over Ukraine-related sanctions violations, Reuters says »

The U.S. Treasury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$146.69

-6.615 (-4.32%)

, LOW

Lowe's

$73.43

-3.4 (-4.43%)

10:27
07/20/17
07/20
10:27
07/20/17
10:27
Recommendations
Home Depot, Lowe's analyst commentary  »

Home Depot and…

HD

Home Depot

$146.69

-6.615 (-4.32%)

LOW

Lowe's

$73.43

-3.4 (-4.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

, NUE

Nucor

$58.99

-1.67 (-2.75%)

10:27
07/20/17
07/20
10:27
07/20/17
10:27
Hot Stocks
Steel Dynamics CEO says flat rolled enviroment steady despite auto »

Industry will follow…

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

NUE

Nucor

$58.99

-1.67 (-2.75%)

X

U.S. Steel

$24.08

-0.39 (-1.59%)

AKS

AK Steel

$6.52

-0.08 (-1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 20

    Jul

  • 25

    Jul

  • 26

    Jul

PFE

Pfizer

$33.60

-0.025 (-0.07%)

, MRK

Merck

$63.18

0.555 (0.89%)

10:26
07/20/17
07/20
10:26
07/20/17
10:26
Hot Stocks
Credit Suisse cuts Pfizer to hold, prefers Merck, J&J »

Credit Suisse downgraded…

PFE

Pfizer

$33.60

-0.025 (-0.07%)

MRK

Merck

$63.18

0.555 (0.89%)

JNJ

Johnson & Johnson

$136.04

0.83 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 09

    Aug

  • 27

    Aug

  • 22

    Sep

10:25
07/20/17
07/20
10:25
07/20/17
10:25
General news
U.S. leading economic index rose 0.6% to 127.8 in June »

U.S. leading economic…

C

Citi

$66.79

0.09 (0.13%)

10:25
07/20/17
07/20
10:25
07/20/17
10:25
Conference/Events
Citigroup to hold a conference call »

CFO Gerspach holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 25

    Jul

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:21
07/20/17
07/20
10:21
07/20/17
10:21
Hot Stocks
Breaking Hot Stocks news story on Steel Dynamics »

Steel Dynamics CEO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

TSLA

Tesla

$325.26

-2.98 (-0.91%)

10:21
07/20/17
07/20
10:21
07/20/17
10:21
Hot Stocks
Citi awaits better Tesla entry point as bulls, bears both make good points »

Citi analyst Itay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

  • 02

    Oct

VRTX

Vertex

$159.69

27.53 (20.83%)

10:20
07/20/17
07/20
10:20
07/20/17
10:20
Options
Large call spread in Vertex Pharm after yesterday's surge »

Large call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

10:20
07/20/17
07/20
10:20
07/20/17
10:20
General news
Treasury Action: longer yields rotated lower again »

Treasury Action: longer…

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:19
07/20/17
07/20
10:19
07/20/17
10:19
Hot Stocks
Breaking Hot Stocks news story on Steel Dynamics »

Steel Dynamics cites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

TSLA

Tesla

$325.26

-2.98 (-0.91%)

, JNJ

Johnson & Johnson

$136.03

0.82 (0.61%)

10:19
07/20/17
07/20
10:19
07/20/17
10:19
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

TSLA

Tesla

$325.26

-2.98 (-0.91%)

JNJ

Johnson & Johnson

$136.03

0.82 (0.61%)

TTS

Tile Shop

$14.83

-0.175 (-1.17%)

SBPH

Spring Bank Pharmaceuticals

$14.20

-0.12 (-0.84%)

DISCA

Discovery

$27.18

1.13 (4.34%)

SNI

Scripps Networks

$76.89

9.87 (14.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

  • 09

    Aug

  • 09

    Aug

  • 02

    Oct

PFE

Pfizer

, RAD

Rite Aid

$2.50

-0.1322 (-5.03%)

10:19
07/20/17
07/20
10:19
07/20/17
10:19
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

PFE

Pfizer

RAD

Rite Aid

$2.50

-0.1322 (-5.03%)

FMSA

Fairmount Santrol

$3.63

-0.245 (-6.33%)

NEWR

New Relic

$47.96

-0.84 (-1.72%)

SND

Smart Sand

$7.87

0.25 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 03

    Aug

  • 03

    Aug

  • 08

    Aug

  • 27

    Aug

  • 29

    Aug

NKE

Nike

$59.31

1.54 (2.67%)

, BGS

B&G Foods

$37.08

1.275 (3.56%)

10:18
07/20/17
07/20
10:18
07/20/17
10:18
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

NKE

Nike

$59.31

1.54 (2.67%)

BGS

B&G Foods

$37.08

1.275 (3.56%)

HPQ

HP Inc.

$18.86

0.155 (0.83%)

RCL

Royal Caribbean

$115.14

2.5775 (2.29%)

BWLD

Buffalo Wild Wings

$122.60

0.65 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

  • 29

    Aug

  • 11

    Sep

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:18
07/20/17
07/20
10:18
07/20/17
10:18
Hot Stocks
Steel Dynamics sees more stabilized scrap environment in 2H »

Comments from Q2 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

$NSD

NASDAQ Market Internals

10:17
07/20/17
07/20
10:17
07/20/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
07/20/17
07/20
10:16
07/20/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
07/20/17
07/20
10:15
07/20/17
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

10:15
07/20/17
07/20
10:15
07/20/17
10:15
General news
Breaking General news story  »

Week of 7/14 EIA Natural…

RAD

Rite Aid

$2.50

-0.129 (-4.90%)

10:11
07/20/17
07/20
10:11
07/20/17
10:11
Hot Stocks
Rite Aid expands Naloxone dispensing program to Michigan, South Carolina »

Rite Aid announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHLB

Berkshire Hills Bancorp

10:10
07/20/17
07/20
10:10
07/20/17
10:10
Hot Stocks
Breaking Hot Stocks news story on Berkshire Hills Bancorp »

Berkshire Hills Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

AMZN

Amazon.com

$1,026.87

2.42 (0.24%)

, GOOG

Alphabet

$970.89

5.49 (0.57%)

10:10
07/20/17
07/20
10:10
07/20/17
10:10
Periodicals
AWS weighs new cloud service based on popular Google software, Information says »

Amazon Web Services…

AMZN

Amazon.com

$1,026.87

2.42 (0.24%)

GOOG

Alphabet

$970.89

5.49 (0.57%)

GOOGL

Alphabet Class A

$992.77

5.82 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

  • 24

    Jul

  • 27

    Jul

TMST

TimkenSteel

$16.00

-0.18 (-1.11%)

, STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:10
07/20/17
07/20
10:10
07/20/17
10:10
Recommendations
TimkenSteel, Steel Dynamics, AK Steel, U.S. Steel, Nucor analyst commentary  »

Cowen would be buying…

TMST

TimkenSteel

$16.00

-0.18 (-1.11%)

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

AKS

AK Steel

$6.52

-0.08 (-1.21%)

X

U.S. Steel

$24.11

-0.36 (-1.47%)

NUE

Nucor

$59.14

-1.52 (-2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 20

    Jul

  • 25

    Jul

  • 26

    Jul

  • 01

    Aug

XBI

SPDR S&P BIOTECH

$79.80

0.69 (0.87%)

10:10
07/20/17
07/20
10:10
07/20/17
10:10
Options
Defensive option play in the SPDR Biotech ETF »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.